The Zhitong Finance App learned that on December 24, the CDE website showed that AstraZeneca (AZN.US) gefurulimab (gefurulimab) was declared for listing in China. According to the progress of clinical trials, it is presumed that the indication declared this time is generalized myasthenia gravis (gMG). Gorulizumab is a mini double antibody (25kD) containing only the C5-targeted heavy chain variable region and an antibody fragment that specifically binds to albumin (Albumin). Smaller molecular weights can lead to better permeability, and binding to albumin can extend its half-life.

The Zhitong Finance App learned that on December 24, the CDE website showed that AstraZeneca (AZN.US) gefurulimab (gefurulimab) was declared for listing in China. According to the progress of clinical trials, it is presumed that the indication declared this time is generalized myasthenia gravis (gMG). Gorulizumab is a mini double antibody (25kD) containing only the C5-targeted heavy chain variable region and an antibody fragment that specifically binds to albumin (Albumin). Smaller molecular weights can lead to better permeability, and binding to albumin can extend its half-life.